Titan Pharmaceuticals Inc Asset Resilience Ratio
Titan Pharmaceuticals Inc asset resilience ratio. Titan Pharmaceuticals Inc (TTNP) has an Asset Resilience Ratio of 3.05% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TTNP defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Titan Pharmaceuticals Inc (2000–2017)
Asset resilience ratio of Titan Pharmaceuticals Inc from 2000 to 2017. This chart shows how Titan Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Read debt load of Titan Pharmaceuticals Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Titan Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Titan Pharmaceuticals Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $361.00K | 3.05% |
| Total Liquid Assets | $361.00K | 3.05% |
Asset Resilience Insights
- Limited Liquidity: Titan Pharmaceuticals Inc maintains only 3.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Titan Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Titan Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Genmab A/S
CO:GMAB |
Biotechnology | 23.50% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653 |
Biotechnology | 1.69% |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX |
Biotechnology | 4.91% |
|
Bachem Holding AG
SW:BANB |
Biotechnology | 0.00% |
|
Viking Therapeutics Inc
NASDAQ:VKTX |
Biotechnology | 72.03% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
Titan Pharmaceuticals Inc Asset Resilience Ratio by Year (2000–2017)
Titan Pharmaceuticals Inc asset resilience ratio by year from 2000 to 2017. The table below shows the annual Asset Resilience Ratio data for Titan Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 4.05% | $361.00K | $8.90 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $18.67 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $13.29 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $20.85 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $18.42 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $24.83 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $10.22 Million | -- |
| 2008-12-31 | 62.68% | $3.57 Million | $5.70 Million | +48.41pp |
| 2007-12-31 | 14.27% | $4.40 Million | $30.84 Million | -13.00pp |
| 2006-12-31 | 27.27% | $4.10 Million | $15.04 Million | -14.41pp |
| 2005-12-31 | 41.68% | $8.23 Million | $19.74 Million | -38.21pp |
| 2004-12-31 | 79.89% | $30.86 Million | $38.63 Million | -1.16pp |
| 2003-12-31 | 81.05% | $39.72 Million | $49.01 Million | -6.26pp |
| 2002-12-31 | 87.32% | $66.30 Million | $75.93 Million | -5.35pp |
| 2001-12-31 | 92.67% | $99.28 Million | $107.13 Million | +10.58pp |
| 2000-12-31 | 82.08% | $97.22 Million | $118.44 Million | -- |
About Titan Pharmaceuticals Inc
As of October 1, 2025, Titan Pharmaceuticals, Inc. was acquired by KE Sdn Bhd, in a reverse merger transaction. Titan Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development of therapeutics for the treatment of chronic diseases. Titan Pharmaceuticals, Inc. was founded in 1991 and is based in New York, New York.